We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis’ first-in-class hypertension treatment Tekturna and sanofi-aventis’ weight-loss drug Acomplia are among several expected 2007 drug launches that are estimated to reach global blockbuster status, according to IMS Health.
Boston Scientific said in a recent SEC filing that it is facing numerous lawsuits, including more than 1,000 cases related to its acquisition of heart-device maker Guidant and a series of patent infringement cases with rival devicemakers.
A pathway for creating and marketing generic biologics could help health plan sponsors and patients save $71 billion over the next 10 years, according to an Express Scripts report.
Domestic pharmaceutical sales in January were approximately 8 percent higher than in the same period a year earlier, but the growth rate has slowed in recent months, according to an IMS Health report.
Technology holds the key to improving drug development through product life cycle management (PLM), which allows for greater collaboration in the development, sale and service of products, industry experts say.
Shire Laboratories’ plan to acquire a smaller specialty drug manufacturer, giving it full control of the marketing and manufacturing of the attention-deficit/hyperactivity disorder (ADHD) drug Vyvanse, could put it in the same market as generic Adderall XR, according to a company source.
Despite a 28 percent increase in profits and an 11 percent rise in sales, AstraZeneca will cut approximately 3,000 jobs to help with anticipated losses from generic competition, the company announced.
Two companies announced they are taking steps to provide easier access to needed medications in developing countries, while an advocacy group claimed a third company is preventing access to HIV medication through an overload of patents.
Bayer is cutting 6,100 jobs as part of its acquisition of Schering AG, the company announced. The cuts, which will eliminate about 5.5 percent of Bayer’s work force, are a necessary part of minimizing the overlap between the two companies, Bayer said.
Medtronic's implantable cardioverter-defibrillator (ICD) direct-to-consumer (DTC) ad campaign helps St. Jude Medical more than it helps Medtronic, according to Lazard Capital Markets.